STAT33m
Lilly expands its Zepbound vial offering, as Hims pulls back on semaglutide
Lilly expands its Zepbound vial offering, as HIMS pulls back on semaglutide, and other biotech news in today's Readout ...
Meet The New Drugs That Can Slow Down Early Alzheimer’s
When people have Alzheimer’s disease, their brains slowly accumulate abnormal clumps of two proteins: amyloid and tau. At ...
Machine learning predicts stable drug forms to prevent efficacy loss
Molecular crystal polymorphism does not sound like something you want in your kitchen, but you've probably had experience ...
Lilly offers weight-loss drugs in vials at a discount to fight competition
Eli Lilly has cut the price for vials of its weight-loss drug Zepbound sold online and expanded the range of doses in an ...
AIM Doses First New Subject in Phase 2 Study of Ampligen and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer
AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the first new subject has been dosed in Phase 2 of the Phase 1b/2 clinical trial involving AIM’s Ampligen ...
Lilly launches higher dose vials of weight-loss drug for $150 less than injector pen
Eli Lilly said on Tuesday it has begun selling higher doses of its popular weight-loss drug Zepbound in vials in the U.S. at ...
ABC Action News2h
Hims and Hers likely to stop selling cheaper versions of GLP-1 medications
The FDA has resolved the shortage of Wegovy and Ozempic, but companies like Hims and Hers may halt sales of compounded ...
Eli Lilly is selling higher-dose vials of Zepbound at a lower price to boost weight loss drug access
Eli Lilly is offering higher-dose vials through its direct-to-consumer website, LillyDirect, which started offering lower ...